The Female Testosterone and/or Estradiol Pellet Insertion Informed Consent Form is a clinical document that confirms a patient understands the procedure, expected benefits, potential risks, and alternatives to subcutaneous hormone pellet therapy before insertion. It is used by hormone-therapy, gynecology, functional medicine, and integrative health practices to support shared decision-making and meet medico-legal documentation requirements before any pellet implantation procedure.
Pellet hormone therapy involves a minor surgical procedure and the long-acting release of testosterone and/or estradiol over three to six months. Because the pellets cannot be easily removed once implanted, written informed consent is essential. The form documents that the patient was informed of the off-label nature of compounded bioidentical hormones, the cardiovascular and oncologic risk discussion, contraception requirements, and the practitioner's explanation of alternatives. It protects both the patient and the practice and is a baseline requirement for most malpractice carriers and state medical boards.
Procedure description. Details how the pellets — typically the size of a grain of rice — are inserted under the skin of the upper hip or buttock through a small incision under local anesthesia, and how they slowly release hormone over several months.
Expected benefits. A summary of the symptoms hormone therapy is intended to address, such as low libido, fatigue, mood changes, vasomotor symptoms, and decreased sense of well-being, while making clear that individual response varies.
Procedural risks. Discussion of bleeding, bruising, swelling, pain, infection at the insertion site, pellet extrusion, and the small risk of needing the site re-opened.
Hormone-related risks. Disclosure of possible acne, increased facial hair, mood changes, fluid retention, breast tenderness, polycythemia (thickened blood requiring annual CBC monitoring), and the potential effect on estrogen-dependent conditions including endometrial hyperplasia, abnormal uterine bleeding, and increased risk of estrogen-sensitive cancers.
FDA status. A clear statement that compounded estradiol and testosterone pellets are not FDA-approved for use in women, that they are prepared by compounding pharmacies under state board oversight, and that the FDA has issued safety statements about compounded hormone therapy.
Contraception and pregnancy. Acknowledgment that testosterone is FDA pregnancy category X and that women of reproductive potential must use reliable contraception and confirm they are not pregnant before insertion.
Alternatives to therapy. A listing of alternatives, including FDA-approved oral, transdermal, vaginal, or injectable hormone preparations and non-hormonal options.
Follow-up and monitoring. The expected lab monitoring schedule, including baseline and follow-up hormone panels, CBC, and lipid panel, plus the timing of re-insertion.
Financial responsibility. Confirmation that pellet therapy is typically not covered by insurance and that the patient understands the cash-pay nature of the service.
Patient signature, date, witness, and clinician signature. The legally required attestations.
1. Send the consent form to the patient electronically before the scheduled procedure so they have time to read it without the pressure of an in-office visit. 2. Pair it with a pre-procedure intake form and a current medication and allergy review. 3. Review the form verbally with the patient before the procedure begins, document the discussion, and answer questions. 4. Capture the patient's electronic signature at the bottom of the form. 5. Route the signed copy to the patient chart and EHR. 6. Provide the patient a copy of the signed consent for their records. 7. Re-consent the patient before each repeat insertion, since clinical circumstances and labs change over time.
| Workflow factor | Paper form | Zentake digital form |
|---|---|---|
| Patient completion before visit | Rare — usually completed in waiting room | Sent by SMS or email before the appointment |
| Signature capture | Wet signature, scanned later | Legally compliant e-signature with audit trail |
| Legibility | Risk of unreadable answers and missed initials | Required fields and validation prevent gaps |
| HIPAA storage | Locked cabinet, manual filing | HIPAA-compliant encrypted cloud storage |
| EHR routing | Manual scan and upload | Direct routing to chart with timestamped record |
| Re-consent for repeat pellets | Refilled by hand each time | Pre-filled patient data, only updates required |
Q1: Is pellet therapy FDA-approved for women?
Compounded estradiol and testosterone pellets are not FDA-approved for use in women. They are prepared by compounding pharmacies under state board of pharmacy oversight, and the FDA has stated that compounded bioidentical hormone therapy lacks evidence of safety and efficacy compared to FDA-approved hormone preparations. This off-label status must be disclosed clearly on the consent form so patients can make an informed choice.
Q2: How long does a pellet insertion procedure take?
The insertion itself typically takes 10 to 15 minutes. After local anesthetic is administered to the upper hip or buttock, a small trocar is used to place the pellets just under the skin through a tiny incision that is then closed with adhesive strips. The patient is usually able to return to non-strenuous activity the same day, with activity restrictions for several days afterward.
Q3: What lab monitoring is required after pellet insertion?
Most practices order baseline and follow-up hormone panels (estradiol, total and free testosterone, SHBG), an annual CBC to monitor for testosterone-induced erythrocytosis, and a lipid panel. Patients with a uterus may require additional monitoring for abnormal uterine bleeding. The exact schedule should be documented in the consent form and aligned with the practice's protocol.
Q4: Can the consent be signed remotely?
Yes. Electronic signatures under the E-Sign Act and UETA are legally binding for healthcare consent forms when the patient's identity is reasonably verified and an audit trail is preserved. Zentake captures the device, IP, timestamp, and signature image so the consent meets state medical board and malpractice carrier requirements.
Q5: Do patients need to re-sign at each insertion?
Yes. Best practice is re-consent at every pellet insertion because clinical status, current medications, lab values, and reproductive plans can change between visits. Zentake's pre-fill workflow speeds re-consent by carrying forward the patient's prior responses and prompting only for updates.
Q6: How does Zentake protect this consent under HIPAA?
All form data is encrypted in transit (TLS 1.2+) and at rest (AES-256), stored in HIPAA-compliant infrastructure, and covered by a Business Associate Agreement. Role-based access controls limit chart access to authorized staff, and every signature event is captured in a tamper-evident audit log.
1. South Carolina Blue Cross Blue Shield. Implantable Hormone Pellets for Females — Medical Policy. southcarolinablues.com.
2. Aetna. Clinical Policy Bulletin: Implantable Hormone Pellets. aetna.com/cpb.
3. Jiang X, et al. The dangers of compounded bioidentical hormone replacement therapy. PMC. pmc.ncbi.nlm.nih.gov.
4. Cleveland Clinic. Bioidentical Hormones: Therapy, Uses, Safety & Side Effects. my.clevelandclinic.org.
Last updated: May 2026.
The leading patient intake platform. HIPAA compliant forms for healthcare providers and organizations. Find out what you're missing!
